Compile Data Set for Download or QSAR
maximum 50k data
Found 88 with Last Name = 'turner' and Initial = 'a'
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238166(US10017502, Example 7 | US9394291, 7)
Affinity DataIC50:  9.5nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238166(US10017502, Example 7 | US9394291, 7)
Affinity DataIC50:  9.5nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404277(US10017502, Example 8b)
Affinity DataIC50:  10nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  10nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  13nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404271(US10017502, Example 6a)
Affinity DataIC50:  13nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProteasome subunit beta type-8(Mus musculus)
The University Of Adelaide

Curated by ChEMBL
LigandPNGBDBM50201035(CHEMBL3907636)
Affinity DataIC50:  14nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238161(US10017502, Example 5a | US9394291, 5a)
Affinity DataIC50:  16nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238161(US10017502, Example 5a | US9394291, 5a)
Affinity DataIC50:  16nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProteasome subunit beta type-8(Mus musculus)
The University Of Adelaide

Curated by ChEMBL
LigandPNGBDBM50069989((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxa...)
Affinity DataIC50:  17nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  40nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  40nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  58nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  58nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  82nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  82nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProteasome subunit beta type-8(Mus musculus)
The University Of Adelaide

Curated by ChEMBL
LigandPNGBDBM50201038(CHEMBL3898621)
Affinity DataIC50:  113nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProteasome subunit beta type-8(Mus musculus)
The University Of Adelaide

Curated by ChEMBL
LigandPNGBDBM50201036(CHEMBL3972546)
Affinity DataIC50:  118nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404265(US10017502, Example 4a)
Affinity DataIC50:  130nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238159(US10017502, Example 4b | US9394291, 4a)
Affinity DataIC50:  130nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  180nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  180nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404258(US10017502, Example 2a)
Affinity DataIC50:  230nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  230nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404265(US10017502, Example 4a)
Affinity DataIC50:  240nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238159(US10017502, Example 4b | US9394291, 4a)
Affinity DataIC50:  240nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404263(2-{(3S or 3R)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,...)
Affinity DataIC50:  270nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  270nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  480nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  480nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProteasome subunit beta type-8(Mus musculus)
The University Of Adelaide

Curated by ChEMBL
LigandPNGBDBM50201037(CHEMBL3978175)
Affinity DataIC50:  483nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  740nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  740nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
TargetEcdysone receptor(Lucilia cuprina)
Csiro Molecular And Health Technologies

Curated by ChEMBL
LigandPNGBDBM50326776(2,3,14,20,22-PENTAHYDROXYCHOLEST-7-EN-6-ONE | CHEM...)
Affinity DataIC50:  900nMAssay Description:Binding affinity to Lucilia cuprina recombinant ecdysone receptor ligand binding domain after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  1.40E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  1.40E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404276(US10017502, Example 8a)
Affinity DataIC50:  1.60E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  1.60E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  1.80E+3nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  1.80E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  1.90E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404273(US10017502, Example 6b)
Affinity DataIC50:  1.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  2.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  2.90E+3nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238162(US10017502, Example 5b | US9394291, 5b)
Affinity DataIC50:  4.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238162(US10017502, Example 5b | US9394291, 5b)
Affinity DataIC50:  4.90E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEcdysone receptor(Lucilia cuprina)
Csiro Molecular And Health Technologies

Curated by ChEMBL
LigandPNGBDBM50326777((2beta,3beta,5beta,22R)-2,3,14,20,22,25-hexahydrox...)
Affinity DataIC50:  5.50E+3nMAssay Description:Binding affinity to Lucilia cuprina recombinant ecdysone receptor ligand binding domain after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEcdysone receptor(Lucilia cuprina)
Csiro Molecular And Health Technologies

Curated by ChEMBL
LigandPNGBDBM50326770(4-isobutyl-5-methylene-2-oxo-1-(2,4,5-trichlorophe...)
Affinity DataIC50:  5.50E+3nMAssay Description:Binding affinity to Lucilia cuprina recombinant ecdysone receptor ligand binding domain after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEcdysone receptor(Lucilia cuprina)
Csiro Molecular And Health Technologies

Curated by ChEMBL
LigandPNGBDBM50326767(4-butyl-1-(2-tert-butyl-5-chlorophenyl)-5-methylen...)
Affinity DataIC50:  5.50E+3nMAssay Description:Binding affinity to Lucilia cuprina recombinant ecdysone receptor ligand binding domain after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEcdysone receptor(Lucilia cuprina)
Csiro Molecular And Health Technologies

Curated by ChEMBL
LigandPNGBDBM50326755(1-(2,5-di-tert-butylphenyl)-4-methyl-5-methylene-2...)
Affinity DataIC50:  6.50E+3nMAssay Description:Binding affinity to Lucilia cuprina recombinant ecdysone receptor ligand binding domain after 3 hrs by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 88 total ) | Next | Last >>
Jump to: